INTRODUCTION
Amyloid A (AA) amyloidosis and atherosclerosis are 2 different diseases, but uncontrolled inflammation plays a significant part in the pathogenesis of both. [1] [2] [3] Amyloidosis is characterized by the extracellular deposition of a protein-like material and classified according to a precursor protein. Secondary AA amyloidosis is a complication of chronic inflammatory disorders, such as familial Mediterranean fever (FMF) and ankylosing spondylitis (AS), [4, 5] in which the amyloid fibrils are derived from serum amyloid A (SAA) protein. SAA, like C-reactive protein (CRP) is produced in the liver in response to proinflammatory cytokines. [6] Patients with inflammatory diseases, such as those with FMF, AS, and systemic lupus erythematous, are considered to have an increased risk for secondary AA amyloidosis and atherosclerosis. [7, 8] Inflammation plays a significant part in the pathogenesis of both diseases, but little is known about the relationship. Carotid intima-media thickness (IMT) is used to define preclinical atherosclerosis. [7, 8] Therefore, the objective of this research was to determine whether inflammatory disease patients with AA amyloidosis have a greater risk of subclinical atherosclerosis than inflammatory disease patients without AA amyloidosis or healthy controls by assessing carotid IMT.
MATERIAL AND METHODS
This was a cross-sectional, observational study. After the Original Article study protocol was approved by the hospital ethics committee, a total of 82 participants were studied. There were 14 inflammatory disease patients with AAA (6 AS, 8 FMF), 34 inflammatory disease patients without AAA (16 AS, 18 FMF), and 34 sex, age, and excluded-criteria matched healthy controls.
All of the patients were non-smokers and at least 18 years of age. Patients with a history of atherosclerotic vascular disease (myocardial infarction, stroke, or peripheral vascular disease), uncontrolled hypertension, diabetes mellitus, malignancy, tuberculosis, acute/chronic infection, or chronic kidney disease were excluded. All of the FMF patients were on colchicine treatment (1.5 mg/day). The diagnosis of FMF was made according to the Tel Hashomer criteria [9] and the diagnosis of AS was made according to the modified New York criteria. [10] Based on renal biopsy findings, 8 FMF patients and 6 AS patients were diagnosed with AA amyloidosis (n=14). Healthy participants were chosen according to the study exclusion criteria.
All of the participants provided a complete history and had a physical examination. Clinical and laboratory assessments of patient with inflammatory disease were performed during an attack-free period, defined based on a lack of clinical symptoms. Blood sampling was carried out after an overnight fast. Laboratory variables of glucose, creatinine, C-reactive protein (CRP), and total cholesterol (T-Chol), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured using routine methods. Body mass index (BMI) was calculated by dividing weight (kilograms) by height (meters squared). Creatinine clearance (CrCl) was calculated according to the CockcroftGault formula. [11] Carotid intima-media thickness measurement Bilateral assessment was made of wall thickness in the common carotid artery (CCA). Carotid IMT was measured as the distance from the leading edge of the first echogenic line (intima interface) to that of the second echogenic line (upper layer of the tunica adventitia). Carotid IMT measurement of both the right and left CCA was performed at 3 points on the far walls in each CCA from 1 cm proximal to the bifurcation of the CCA. The 3 locations were then averaged to produce a mean IMT for each side. The carotid IMT was reported as the average thickness of both CCAs.
Statistical analysis
All analyses were conducted using SPSS for Windows, Version 15.0 (SPSS, Inc., Chicago, IL, USA) and the mean±SD or median (interquartile range) was used to present the data, as applicable. The mean differences between groups were compared using one-way analysis of variance or the Kruskal-Wallis test, according to the distribution. A post hoc Tukey Honest Significant Difference test was used to determine which group differed from the others. A twosided p value of <0.05 was considered statistically significant.
RESULTS
The study population included 26 FMF, 22 AS patients, and 34 healthy participants. The 14 members of the amyloidal inflammatory disease group were 8 FMF and 6 AS patients. Table 1 provides a summary of the clinical features and laboratory values of all of the study groups. Differences between groups as to age, sex, BMI, CrCl, systolic blood pressure, diastolic blood pressure, serum level of T-Chol, LDL, HDL, or fasting blood glucose, were not significant. T-Chol, LDL, HDL, fasting glucose, and creatine were measured at normal intervals. Serum CRP levels were significantly higher in the patients with amyloidal inflammatory disease compared with the control group (p<0.001) ( Table 1 ).
The carotid CRP difference was statistically higher in amyloidal inflammatory disease patients (p<0.001). As shown in Figure 1 and Table 2 , the carotid IMT was determined to be significantly greater in the amyloidal inflammatory disease patients when compared with the non-amyloidal inflammatory disease patients and the healthy controls 
DISCUSSION
The results of this study demonstrated that the carotid IMT was significantly greater in the patients with amyloidal inflammatory disease than in those with non-amyloidal inflammatory disease and the healthy participants. To the best of our knowledge, this is the first study to demonstrate an association between amyloidosis and carotid IMT in inflammatory disease patients matched for major atherosclerotic risk factors.
Atherosclerosis is a slow, progressive inflammatory disease. The presence of atherosclerosis can be identified using various noninvasive imaging techniques, such as measuring carotid IMT with ultrasound, which is a widely accepted screening method of subclinical atherosclerosis. [12] Excessive carotid IMT is associated with atherosclerosis in the coronary arteries. [13] Previous studies have demonstrated that patients with inflammatory disease have greater carotid IMT levels, and our results, which revealed an increased carotid IMT in the group with inflammatory disease, are consistent with previous study data. [7, 8] The study data were collected with care and matched for major risk factors for atherosclerosis, including smoking status and diabetes mellitus. According to our findings, AA amyloidosis was associated with carotid IMT, though there are several possible explanations for the relationship observed between carotid arterial wall thickness and AA amyloidosis. First, there is a possible association between AA amyloidosis and inflammation. Systemic AA amyloidosis is a long-recognized, severe complication of several chronic inflammatory diseases. Inflammatory diseases and atherosclerosis share a number of similarities, including inflammatory cell activation and the production of pro-inflammatory cytokines. [14] [15] [16] Patients with inflammatory diseases have an elevated level of CRP, a marker of inflammation relevant to increased cardiovascular risk. [14, 17] Among various markers of inflammation, CRP level was suggested as a particularly powerful predictor of cardiovascular disease independent of serum lipid levels in a general population study in the United States. [14] It is also hypothesized that CRP may be causally involved in the pathophysiology of atherosclerosis and its complications. [17] Tanasescu et al. [18] reported that the IMT of inflammatory disease patients was correlated with CRP level. Secondary amyloidosis occurs in 5% of patients with poorly controlled chronic inflammatory disease, mainly AS and FMF. [2, 19] The low-level inflammatory reaction may lead to an increase in arterial wall thickness. As supporting data, we also found that the mean CRP level was greater in the inflammatory disease patient group without amyloidosis than in the healthy control group. However, the highest mean CRP level was in the group of inflammatory disease patients who had amyloidosis.
A second feasible explanation for the increased IMT in amyloidosis patients may be SAA. SAA is a major inflammatory molecule and AA amyloid fibrils are derived from SAA. [20] An elevated level of circulating SAA is present in secondary amyloidosis patients as well as patients with atherosclerosis. [21] SAA has been suggested as a marker of atherosclerotic disease and it has been found in many cell types in atherosclerotic lesions. [22] [23] [24] SAA level was not measured in our study, and represents an issue that should be addressed in future research.
The third cause may renal involvement in AA amyloidosis. This can be a cause of proteinuria, nephrotic syndrome, and/or renal dysfunction. [25] The results of a large cohort study and a meta analysis indicated that sustained decreases in estimated glomerular filtration rate (eGFR) below 60 mL/minute/1.73 m 2 were associated with increased rates of atherosclerotic diseases. [26, 27] Furthermore, studies have described increased cardiovascular mortality and morbidity risk in renal disease associated with amyloidosis. [28] [29] [30] In this study, AA amyloidosis patients were diagnosed based on renal biopsy findings, and the mean level of blood creatinine and eGFR were in the normal range, with no significant difference between groups; however, we calculated the eGFR using the Crockcroft-Gault formula and it may not be accurate in patients with factors affecting creatinine production because serum creatinine is a main component of the formula. Direct measurement of CrCl using 24-hour urine creatinine clearance data would be helpful in a similar population group in future studies.
Amyloidosis series reported from Turkey are generally associated with FMF, but in the colchicine-treatment era, FMF patients with amyloidosis are becoming extremely rare and it is difficult to recruit cases. [4] Therefore, the number of patients in the amyloidosis group was relatively small and the study groups consisted of mixed inflammatory disease patients.
Conclusion
Our results suggested that increased arterial wall thickness is associated with the presence of amyloidosis, possibly due to an increase in atherosclerotic changes related to inflammation. In order to confirm these correlations, prospective studies with a larger number of participants are warranted.
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